SCHEMBL3658652

SCHEMBL3658652

CCCC(=O)c1ccc(OC)cc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.64
RAB9A P51151 6/20 0.64
HPGD P15428 6/20 0.62
ALDH1A1 P00352 4/20 0.62
CYP3A4 P08684 4/20 0.62
MAPK1 P28482 3/20 0.62
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
MAPT P10636 2/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
ATM Q13315 1/20 0.57
TAS1R3 Q7RTX0 1/20 0.57
TAS1R1 Q7RTX1 1/20 0.57
ALOX15 P16050 2/20 0.56
TSHR P16473 2/20 0.56
RECQL P46063 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
CYP2C19 P33261 4/20 0.55
LMNA P02545 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660724 0.90 HTT (0.65) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3662392 0.89 HTT (0.72) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3662822 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3658080 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3658682 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3658608 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3663202 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3660499 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3658257 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL3659698 0.88 HTT (0.70) NPC1RAB9AHPGDALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126835-B1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12516038-B2 Inhibitors of antigen presentation by HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-01-06 US disclosed
US-20230150985-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2023-05-18 US disclosed
EP-4126835-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR Janssen Pharmaceutica NV (BE) 2023-02-08 EP disclosed
WO-2021198283-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2021-10-07 WO disclosed
US-9364424-B2 Topical cosmetic skin lightening compositions and methods of use thereof STIEFEL LABORATORIES, INC. (US) 2016-06-14 US disclosed
US-20160074315-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. 2016-03-17 US disclosed
EP-2219600-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2010-08-25 EP disclosed
WO-2009067095-A1 TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF STIEFEL LABORATORIES, INC. (US) 2009-05-28 WO disclosed
EP-1602354-B1 Use of polyglutamic acid or its salts MEIJI SEIKA KAISHA (JP) 2008-11-05 EP disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair MEIJI SEIKA KAISHA, LTD. (JP) 2006-07-27 US disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed
EP-1602354-A1 HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR Meiji Seika Kaisha, Ltd. (JP) 2005-12-07 EP disclosed
US-3937808-A SUN TANNING AND HARI PROTECTING ACID SALTS OF AMINOMETHYL-O-HYDROXYPHENONES COMPOSITIONS GAF CORPORATION (US) 1976-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150985-A1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR HLA-DRB1, CD74, HLA-C NPC1 196/4885RAB9A 2175/4885HPGD 370/4885
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair CUTA, COL14A1, PRKDC NPC1 4845/4885RAB9A 3880/4885HPGD 3285/4885
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR NPC1 3666/4885RAB9A 1846/4885HPGD 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.